Abstract: Monoclonal antibodies to human antigens present on a majority of human cells are described. These mAbs have use in a method for isolating mAb for less expressive antigens, such as cancer antigens, or other antigens associated with particular abnormalities, disorders or disease state. The latter mAbs may be weaker than or not present to such an extent as the first mentioned mAbs. For example, these less expressive mAbs would be useful for cancer diagnosis, especially in the early stages, and for cancer treatment as well where the cancer cell is the target cell for the mAb. The mAb can be tagged with a tissue destructive agent such as a radio-label, a toxin, a chemical poisen, and the like. Some of the mAbs described, subset tumors of particular types and so are useful for tumor subclassification. The mAbs described are also useful in analyzing the properties and functions of their respective antigens in human cells.

Abstract: Cell surface gangliosides are presumed to play a role in cell growth and differentiation. Using monoclonal antibodies directed against G.sub.D3, a disialoganglioside expressed predominantly by cells of neuroectodermal origin, we have found that G.sub.D3 is expressed by a subpopulation of cells of the immune system including: a) fetal thymocytes in subcortical regions and near vessels, 2) lymph node lymphocytes in interfollicular areas and near vessels, and 3) a small subset of T cells in the peripheral blood. Mouse monoclonal antibodies (two IgGs, one IgM and F(ab').sub.2 fragments) reacting with G.sub.D3 were found to stimulate proliferation of T cells derived from peripheral blood. Proliferation induced by binding to G.sub.D3 could be augmented by exogenous IL-2, PMA, PHA or Protein A.

Abstract: The present invention provides a vaccine for stimulating or enhancing in a subject to whom the vaccine is administered, production of antibodies directed against 9-O-acetyl GD3 ganglioside comprising an amount of purified 9-O-acetyl GD3 ganglioside effective to stimulate or enhance antibody productionThis invention was made with government support under Grant Numbers CA-40532 and CA-43971, National Cancer Institute, Department of Health and Human Services. Accordingly, the U.S. Government has certain rights in the invention.

Abstract: This invention provides a method of identifying mesenchymal tissues as normal, proliferatively active or malignant. This invention also provides a method of distinguishing subsets of sarcomas with distinctive antigenic phenotypes. This invention also provides a method of diagnosing mesenchymal tumors. Finally, this invention provides a monoclonal antibody designated G171 and the hybridoma cell line producing said monoclonal antibody (ATCC No. HB9254).

Abstract: A process is provided for the purification of a proteinaceous physiologically active substance having antitumor activity, which is induced by administering to a rabbit at least one substance having a capacity for stimulating reticuloendothelial system and then injecting endotroxin from a Gram-negative bacterium into the rabbit. The process comprises contacting a crude solution of said proteinaceous physiologically active substance with a basic anion exchanger to have said physiologically active substance adsorbed on the anion exchanger, eluting the adsorbed physiologically active substance, and subjecting the eluate containing said physiologically active substance to gel filtration with a gel suitable for separation of a substance with a molecular weight in the range of 30,000 to 70,000. The purified preparation of said physiologically active substance thus obtained may be used as an antitumore agent for the treatment of malignant tumors.

Abstract: This invention provides a monoclonal antibody, produced by the hybridoma cell line designated GXM1, which specifically binds to a human class 1tumor antigen. This invention also provides a human monoclonal antibody, produced by a hybridoma cell line designated HJM1, which specifically binds to each of the ganglioside antigens GD2, GD3, GM3 and GD1b. This invention further provides a human monoclonal antibody, produced by a hybridoma cell line designated FCM1, which specifically binds to the ganglioside antigens GM3 and GD1a. Finally, this invention provides a human monoclonal antibody, produced by a hybridoma cell line designated DSM1, which specifically binds to a human class 2 tumor protein antigen.

Abstract: Four monoclonal antibodies are found which selectively identify prostate cancer. These monoclonals are therefore useful in diagnosis, differential diagnosis and treatment of prostate cancer.

Abstract: Antigenic profiles of renal carcinoma specimans developed with panels of monoclonal antibodies derived from several different tissues serve as useful clinical indicators for cancer type, cancer subset as well as histiogenesis and prognosis indicators.

Abstract: Human TNF(LuKII) having a specific activity of at least 1.5.times.10.sup.5 units per milligram of total protein is produced by contacting a TNF-containing protein composition, which has been harvested from human cell lines of hematopoietic origin or recombinant origin, in separate adsorption stages with glass beads, lentil lectin bound to Sepharose, and procion red agarose, thereby selectively to adsorb TNF in each stage, while leaving some impurities unadsorbed, each contact stage being followed by contact of the adsorbent with an eluant thereby to obtain a solution of more highly purified TNF after each stage. The purified human TNF(LuKII) is used to produce monoclonal antibodies against TNF(LuKII) and such antibodies can be used to assay samples for the presence of TNF(LuKII).

Abstract: A panel of monoclonal antibodies produced from normal human lung fibroblasts and human lung tumors as immunogen is used to diagnose the presence of lung tumors and differentiate between those which are benign and those which are cancerous.

Abstract: Three new monoclonal antibodies, MU78, MT334, and MQ49, and the hybridoma cell lines producing these, are disclosed. The antibodies specifically bind to mucin-like antigens with distribution over various carcinomas.

Abstract: Monoclonal antibodies to specific cell surface antigens of human choriocarcinoma, teratocarcinoma, and normal trophoblasts are disclosed. Additionally, panels of monoclonal antibodies which may be used in phenotyping cell and tissue samples are disclosed as well.

Abstract: Monoclonal antibody recognizing human melanoma cells, method of production and use.

Abstract: Monoclonal antibody TA99, which specifically binds to a pigmentation associated antigen present on melanoma cells is described. Additionally, the hybridoma cell line deposited with the ATCC under Accession Number HB 8704 from which the antibody is derived, as well as methods for using the antibody are described.

Abstract: A process for predicting the sensitivity of cells, e.g., tumor cells, to the effects of tumor necrosis factor or lymphotoxin involving ascertaining the binding of the tumor necrosis factor or lymphotoxin to the cells, i.e., measuring the number of receptors on the cells.

Abstract: Antibody-producing hybridoma cell lines made by fusion of NS/1 cells with spleen cells of mice after immunization with human teratocarcinoma cells are presented. Monoclonal antibodies from these cell lines recognize the K4, K2 and P12 antigenic systems and are thus useful in detecting and differentiating between normal and cancerous cells. These monoclonal antibodies are especially useful in pathologic analysis of human tumors, especially teratocarcinomas.

Abstract: Human monoclonal antibodies (HmAbs) capable of reacting with cytokeratin are disclosed. It has been found that HmAbs De8, M54, M307, Hull, C29, Hu22 and Pa24 may be used to detect these cytoskeletal proteins in various cells. By means of these HmAbs the embryological origin of cells may be determined. This information may be used to determine the possible tissue source of metastasized tumors and greatly affects the management of these cancers.

Abstract: A panel of monoclonal antibodies is developed for use in diagnosis and treatment of renal carcinoma. One monoclonal antibody F.sub.31 reacts with 80% of renal carcinoma. The area of overlap of reactivity of monoclonal antibodies F.sub.31, F.sub.23, S.sub.4, S.sub.23 and S.sub.27 is the site of origin of most renal carcinomas. Reactivity with this panel of monoclonal antibodies localizes most renal carcinoma and is a vehicle for early diagnosis and treatment.

Abstract: Human monoclonal antibodies (HmAbs) capable of reacting with cell surface antigens and intracellular components are disclosed. It has been found that HmAbs Ev248, Ch-5, Ch-13, Te-39, Hu44, Ge-1, Gr-431, Gr169 and Sp909 may be used to detect these antigens in various cells. By means of these HmAbs malignant cells may be determined. This information may be used to screen metastasized tumors and primary tumors for tissue source and greatly affects the management of these cancers.

Abstract: Human monoclonal antibodies which specifically bind to antigens found on cell surfaces of renal, lung, and breast cancer cells, intracellular cytoskeletal antigens, nuclear antigens, and cytoplasmic reticular antigens are disclosed. The antibodies are the product of hybridoma cell lines, where the immortal cell line may be, e.g., a human cell line, or a murine cell line.